Harbour BioMed and ProBioGen Agree on a GlymaxX® License to Fast-Track Cell Line Development Projects
Harbour BioMed and ProBioGen Agree on a GlymaxX® License to Fast-Track Cell Line Development Projects
BERLIN, Germany and SHANGHAI, China, February 02, 2021 / B3C newswire / -- ProBioGen AG and Harbour BioMed today jointly announced their agreement on a cell line development project and application of the ADCC-enhancement technology GlymaxX®.
Harbour BioMed contracted ProBioGen for the advancement of one of their clinical programs, an antibody with ADCC as mode-of-action. For the enhancement of such antibody’s ADCC, ProBioGen will apply its proprietary GlymaxX® technology. The GlymaxX® technology enables flexible and reversible adjustment of the antibody fucosylation level – from afucosylated to fully fucosylated. This technology is compatible with the CHO.RiGHT® cell line development platform and DirectedLuck™ Transposase. With DirectedLuck™, ProBioGen is now offering fast-track programs, also realized for this Harbour BioMed project.
Jingsong Wang, Founder, CEO and Chairman at Harbour BioMed said: “The combination of ProBioGen’s reputation for outstanding cell lines and their technologies offered alongside our own platforms, convinced us of the rapid progress we can make to bring this and other antibody candidates to the clinic. We are looking forward to working with the ProBioGen team through this exciting collaboration.”
“The ProBioGen team is thrilled to start this cooperation with Harbour BioMed. Using our elegant technologies that combine high, tunable potency and superior productivity with highest development speed, we are happy to advance Harbour BioMed’s pipeline, developed with their clever Harbour Mice® platform”, continued Dr. Volker Sandig, Chief Scientific Officer of ProBioGen and co-inventor of GlymaxX® and DirectedLuck™.
Editor Details
-
Company:
- PharmiWeb.com
-
Name:
- PW Editor
- Email:
-
Telephone:
- +441344851506